New Content Available in LEARNMD

LEARNMD is the NMD4C’s online educational platform, offering talks and sessions on a wide range of neuromuscular topics presented by leading clinical and scientific experts worldwide. Since its launch in fall 2024, we have been working continuously to develop and add new content for our members. We’re excited to share what’s new on LEARNMD in February 2025!

 

European Reference Network – Neuromuscular Disease (ERN EURO-NMD) educational webinars

We’re excited to share that we have established a collaborative agreement with the ERN EURO-NMD to share the extensive catalogue of ERN EURO-NMD educational webinars in the LEARNMD platform! Over 70 videos from ERN EURO-NMD are now available to watch, with additional webinars in the process of being added.

National Neuromuscular Lecture Series

The weekly National Neuromuscular Lecture Series (NNLS) is our year-long CPD-accredited curriculum for neuromuscular fellows, containing 41 topics which constitute a comprehensive base of neuromuscular knowledge, with a weekly lecture presented by subject-matter experts on each topic. We have been working with speakers to allow these talks to be added to LEARNMD and are pleased to share that NNLS lectures from January 2025 will be available on the platform!

Multi-Disciplinary Care in NMDs lecture series

The Multi-Disciplinary Care of Neuromuscular Diseases lecture series is a new 24-topic CPD-accredited webinar series from the NMD4C, designed as an advanced curriculum for neurologists, physiatrists and neuromuscular fellows to learn fundamentals of multi-disciplinary care for patients across a range of neuromuscular conditions. We have been working with speakers to allow these talks to be added to LEARNMD and are pleased to share that all lectures in the series will be available on the platform!

Monthly Neuromuscular Educational Webinars

We continue to share our CPD-accredited monthly educational webinars on LEARNMD, with recordings of each monthly talk available soon after the presentation date. (The specialized quarterly Neuromuscular Mystery Case Rounds webinars are not available on LEARNMD.)

 

We hope that you take advantage of these training and learning resources on LEARNMD. The platform is available to all clinicians and researchers who are members of the NMD4C. Instructions on how to log in or create your LEARNMD account are available here.

 

All three of our National Neuromuscular Lecture Series, Multi-Disciplinary Care in NMDs lecture series, and Monthly Neuromuscular Educational Webinars are self-approved group learning activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. Certificates of attendance can only be issued for attending live – check out our list of upcoming webinars and register to join us at future live sessions!

 

For any questions about LEARNMD or the content, please contact our curriculum coordinator Victoria Larocca at .

LEARNMD content update - February 2025

Read next...

Hope On The Horizon: Trials Treatments and Therapies for DMD, DM1 and MG

Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG

Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!

Website - 2026 NMD4C Awards Now Open

2026 Awards Now Open for Nominations!

We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.

AGAMREE (vamorolone) Approved treatment for DMD in Canada

A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada

Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.